Related references
Note: Only part of the references are listed.Tumor-Infiltrating Lymphocyctes in Triple-Negative Breast Cancer Update for 2020
Lauren C. Brown et al.
CANCER JOURNAL (2021)
Atezolizumab and nab-Paclitaxel in Advanced Triple-Negative Breast Cancer: Biomarker Evaluation of the IMpassion130 Study
Leisha A. Emens et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2021)
Pembrolizumab for Early Triple-Negative Breast Cancer
Peter Schmid et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Tumoral PD-1(hi)CD8(+) T cells are partially exhausted and predict favorable outcome in triple-negative breast cancer
Liang Guo et al.
CLINICAL SCIENCE (2020)
Transcriptional and Functional Analysis of CD1c+ Human Dendritic Cells Identifies a CD163+ Subset Priming CD8+CD103+ T Cells
Pierre Bourdely et al.
IMMUNITY (2020)
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial
Javier Cortes et al.
LANCET (2020)
Angiopoietin-2 as a Biomarker and Target for Immune Checkpoint Therapy
Xinqi Wu et al.
CANCER IMMUNOLOGY RESEARCH (2017)
Mutual regulation of tumour vessel normalization and immunostimulatory reprogramming
Lin Tian et al.
NATURE (2017)
Dual angiopoietin-2 and VEGFA inhibition elicits antitumor immunity that is enhanced by PD-1 checkpoint blockade
Martina Schmittnaegel et al.
SCIENCE TRANSLATIONAL MEDICINE (2017)
QuPath: Open source software for digital pathology image analysis
Peter Bankhead et al.
SCIENTIFIC REPORTS (2017)
Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma
Jeffrey J. Wallin et al.
NATURE COMMUNICATIONS (2016)
Role of vascular density and normalization in response to neoadjuvant bevacizumab and chemotherapy in breast cancer patients
Sara M. Tolaney et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2015)
Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab A Secondary Analysis of the NeoALTTO Trial
Roberto Salgado et al.
JAMA ONCOLOGY (2015)
Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy
Yuhui Huang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Angiopoietin 2 Stimulates TIE2-Expressing Monocytes To Suppress T Cell Activation and To Promote Regulatory T Cell Expansion
Seth B. Coffelt et al.
JOURNAL OF IMMUNOLOGY (2011)
Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors
RT Tong et al.
CANCER RESEARCH (2004)
Share Paper
